跳至主要内容
临床试验/NCT04049591
NCT04049591招募中不适用

A Randomized Trial of Higher vs. Lower Dose Heparin for PCI

Population Health Research Institute1 个研究点 分布在 1 个国家目标入组 16,000 人开始时间: 2022年3月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
16,000
试验地点
1
主要终点
Number of Participants with any of the following: death, myocardial infarction or target vessel revascularization

研究概览

简要总结

HD PCI is a multicenter, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing elective percutaneous coronary intervention (PCI).

详细描述

The primary objective of HD PCI is to compare the effect of a policy of higher dose heparin (100 U/kg) use to a policy of lower dose heparin (70 U/kg) use on death, myocardial infarction (MI) or target vessel revascularization (TVR) in patients undergoing elective percutaneous coronary intervention (PCI).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients undergoing elective PCI

排除标准

  • Age <18 years
  • Planned chronic total occlusion PCI
  • Non-resident precluding follow up through local registries
  • Hospital (Cluster) Eligibility Criteria
  • Hospitals will be eligible to participate if they meet the following criteria:
  • Submit PCI procedure data to a compatible registry that is able to provide data for the trial
  • Site agrees to manage patients as per the higher or lower dose heparin policy in place during the given crossover period

研究组 & 干预措施

Higher Dose Unfractionated Heparin Treatment Period

Active Comparator

A centre wide policy of administering 100 U/kg bolus of intravenous unfractionated heparin (UFH) for elective percutaneous coronary intervention (PCI) procedures will be implemented during the Higher Dose UFH treatment period.

干预措施: Higher Dose UFH (Drug)

Lower Dose Unfractionated Heparin Treatment Period

Active Comparator

A centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures will be implemented during the Lower Dose UFH treatment period.

干预措施: Lower Dose UFH (Drug)

结局指标

主要结局

Number of Participants with any of the following: death, myocardial infarction or target vessel revascularization

时间窗: up to 30 days after PCI

次要结局

  • Number of Participants with major bleeding(up to 30 days after PCI)
  • Number of Participants with any of the following: death, myocardial infarction, target vessel revascularization or major bleeding(up to 30 days after PCI)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验